The Psoriasis Study of Health Outcomes (PSOHO) in Biologic-Naive and -Experienced Patients: Results from the First 217 Patients
Author(s)
Costanzo A1, Pinter A2, Lynde C3, Tsai TF4, Schuster C5, Brnabic A5, Reed C5, Hill J6, Riedl E5, Radtke MA7
1Humanitas University, Milan, Italy, 2University Hospital Frankfurt, Frankfurt am Main, Germany, 3Lynde Institute for Dermatology, Markham, ON, Canada, 4National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 5Eli Lilly and Company, Indianapolis, IN, USA, 6Eli Lilly and Company, Basingstoke, IN, UK, 7Dermatologikum Hamburg GmbH, Hamburg, Germany
OBJECTIVES The Psoriasis Study of Health Outcomes (PSoHO) is a 3-year international, observational cohort study of treatment outcomes in adult patients with moderate-to-severe plaque psoriasis (PsO). METHODS PSoHO’s primary objectives are to compare the proportion of patients achieving ≥90% improvement in Psoriasis Area and Severity Index score (PASI90) and/or static Physician Global Assessment (sPGA) score 0/1 at week 12 (W12) between cohorts receiving anti-IL-17A biologics (ixekizumab/secukinumab) versus all other approved biologics. This subgroup analysis describes W12 effectiveness in the first 217 enrolled patients with chronic, moderate-to-severe PsO who are initiating (bio-naïve) or switching (bio-experienced) biologics. RESULTS The overall patient population was 65.0% (n=141) bio-naïve (n=65 received anti-IL-17A biologics, n=76 other biologics) and 35.0% (n=76) bio-experienced (n=35 received anti-IL-17A biologics, n=41 other biologics); 60.5%, 23.7%, and 15.8% had previous treatment with 1, 2, or ≥3 biologics, respectively. Baseline mean PASI score, mean disease duration (years), and proportion with a co-morbid psoriatic arthritis (PsA) diagnosis were 16.7 (SD:7.7), 16.5 (SD:13.0), and 20.6% for bio-naïve patients, and 13.1 (SD:9.5), 22.1 (SD:13.9), and 48.7% for bio-experienced patients, respectively. At W12, 70.8% (anti-IL-17A) and 42.1% (other biologics) of bio-naïve patients, and 50.0% (anti-IL-17A) and 24.4% (other biologics) of bio-experienced patients achieved PASI90. Additionally, PASI100 was achieved by 43.1% (anti-IL-17A) and 18.4% (other biologics) of bio-naïve patients, and 29.4% (anti-IL-17A) and 12.2% (other biologics) of bio-experienced patients at W12. The proportion of patients achieving sPGA0/1 at W12 was 84.6% (anti-IL-17A) and 64.5% (other biologics) of bio-naïve patients, and 65.7% (anti-IL-17A) and 41.5% (other biologics) of bio-experienced patients. CONCLUSIONS Preliminary results from this subgroup in a real-world setting suggest that bio-experienced patients differ in biologics responsiveness to bio-naïve patients, and have more severe disease, as evidenced by the frequency of concomitant PsA. These results reflect the high efficacy of anti-IL-17A biologics observed in randomised clinical trials.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PBI1
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment, Clinician Reported Outcomes
Disease
Biologics and Biosimilars